Reaction

Lymphadenopathy Mediastinal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,876 reports · 86 co-occurring drugs

As of the last recalculation, Lymphadenopathy Mediastinal appears in 1,876 FAERS reports alongside 86 co-occurring drug terms. The strongest observed disproportionality signal is EXEMESTANE (PRR 32.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Exemestane	60	32.1	32.2
Ganciclovir	20	21.9	21.9
Fulvestrant	63	21.9	21.9
Ganciclovir Sodium	20	21.2	21.2
Pyrazinamide	17	20.3	20.3
Everolimus Tablets	30	20.2	20.2
Goserelin	23	19.2	19.3
Rifampicin	14	15.5	15.5
Regorafenib	16	15.4	15.4
Letrozole	79	14.8	14.8
Pemetrexed	27	14.2	14.2
Letrozole Tablets	59	14.0	14.0
Isoniazid	20	13.8	13.8
Polatuzumab Vedotin	12	13.7	13.7
Chlorhexidine Gluconate	11	13.4	13.4
Zoledronic Acid	46	13.0	13.0
Sorafenib	24	13.0	13.0
Pemetrexed Disodium	42	12.5	12.5
Gefitinib	10	12.4	12.4
Everolimus	53	11.9	11.9
Gemcitabine	41	11.8	11.8
Carboplatin	123	11.4	11.4
Paclitaxel (Aibumin-Bound)	81	11.4	11.4
Ribociclib	31	11.1	11.1
Moxifloxacin Hydrochloride	20	11.1	11.1
Paclitaxel	94	11.0	11.0
Ado-Trastuzumab Emtansine	8	10.6	10.6
Gemcitabine Hydrochloride	47	10.1	10.1
Bendamustine Hcl	13	9.4	9.4
Doxorubicin Hydrochloride	27	9.3	9.3
Panitumumab	13	9.3	9.3
Anastrozole	30	9.2	9.2
Vincristine Sulfate	24	9.2	9.2
Quinine	7	9.1	9.1
Tenofovir Disoproxil Fumarate Tablets	7	9.0	9.0
Anastrozole Tablets	17	8.9	8.9
Pazopanib Hydrochloride	21	8.7	8.7
Busulfan	12	8.5	8.5
Cisplatin	58	8.5	8.5
Erlotinib	7	8.0	8.0
Efavirenz	8	8.0	8.0
Adalimumab-Fkjp	32	7.8	7.8
Salmeterol Xinafoate	6	7.7	7.7
Capecitabine	61	7.6	7.6
Bleomycin Sulfate	7	7.5	7.5
Dabrafenib	14	7.4	7.4
Vemurafenib	8	7.4	7.4
Valganciclovir Hydrochloride Powder,	8	7.3	7.3
Ipilimumab	28	7.3	7.3
Bevacizumab	78	7.2	7.3
Pembrolizumab	65	7.1	7.1
Lamivudine	19	6.9	6.9
Filgrastim	23	6.9	6.9
Fluorouracil Cream, 0.5%	45	6.7	6.7
Darunavir	9	6.6	6.6
Lamivudine Oral	15	6.6	6.6
Fluorouracil	45	6.6	6.6
Doxorubicin	51	6.5	6.5
Nivolumab	55	6.5	6.5
Oxaliplatin	41	6.2	6.2
Erlotinib Hydrochloride	7	6.2	6.2
Trastuzumab	37	6.1	6.1
Posaconazole Delayed-Release	6	6.1	6.1
Cyclophosphamide Injection, Solution	92	6.0	6.0
Cyclophosphamide	92	6.0	6.0
Cyclophosphamide For Injection	92	6.0	6.0
Docetaxel Anhydrous	34	5.7	5.7
Docetaxel	34	5.7	5.7
Trametinib	12	5.5	5.5
Atezolizumab	19	5.5	5.5
Fluticasone Furoate And Vilanterol Trifenatate	17	5.3	5.3
Crizotinib	6	5.3	5.3
Etoposide	34	5.2	5.2
Ifosfamide	10	5.2	5.2
Alpelisib	4	5.1	5.1
Durvalumab	9	4.9	4.9
Pertuzumab	12	4.9	4.9
Osimertinib	14	4.9	4.9
Niraparib	9	4.5	4.5
Palbociclib	33	3.9	3.9
Romiplostim	5	3.7	3.7
Lapatinib	5	3.6	3.6
Encorafenib	3	3.4	3.4
Abiraterone	4	3.3	3.3
Pirfenidone	11	3.0	3.0
Tafamidis	3	2.8	2.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.